Compare Stocks: MOLN, NVCT, CLYM, and DBVT

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
CLYM Climb Bio	$10.91 +6.0%	$13.87	$1.63 ▼ $18.33	$591.02M	-0.04	1.33 million shs	515,487 shs
DBVT DBV Technologies	$9.11 +2.7%	$12.50	$8.85 ▼ $26.18	$557.73M	-1.04	375,708 shs	432,283 shs
MOLN Molecular Partners	$3.75 +2.6%	$4.15	$3.52 ▼ $5.36	$147.37M	1.11	1,691 shs	3,304 shs
NVCT Nuvectis Pharma	$18.93 +5.2%	$21.73	$5.55 ▼ $29.27	$587.59M	-0.24	216,320 shs	156,862 shs

7 Blue-Chip Stocks to Add To Your Forever Portfolio

A strong long-term portfolio starts with companies that can survive recessions, inflation, changing consumer habits, and shifting market leadership.

This report names seven blue-chip stocks across technology, retail, consumer staples, healthcare, networking, sporting goods, and utilities that offer investors a mix of stability, income, growth, and staying power.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
CLYM Climb Bio	-0.19%	-3.92%	-29.33%	-18.20%	+447.34%
DBVT DBV Technologies	-1.77%	-9.21%	-28.18%	-40.31%	-43.32%
MOLN Molecular Partners	-0.54%	-8.50%	-10.12%	-10.10%	+2.53%
NVCT Nuvectis Pharma	-0.83%	-11.29%	-22.91%	-3.23%	+198.51%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
CLYM Climb Bio	$10.91 +6.0%	$13.87	$1.63 ▼ $18.33	$591.02M	-0.04	1.33 million shs	515,487 shs
DBVT DBV Technologies	$9.11 +2.7%	$12.50	$8.85 ▼ $26.18	$557.73M	-1.04	375,708 shs	432,283 shs
MOLN Molecular Partners	$3.75 +2.6%	$4.15	$3.52 ▼ $5.36	$147.37M	1.11	1,691 shs	3,304 shs
NVCT Nuvectis Pharma	$18.93 +5.2%	$21.73	$5.55 ▼ $29.27	$587.59M	-0.24	216,320 shs	156,862 shs

7 Blue-Chip Stocks to Add To Your Forever Portfolio

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
CLYM Climb Bio	-0.19%	-3.92%	-29.33%	-18.20%	+447.34%
DBVT DBV Technologies	-1.77%	-9.21%	-28.18%	-40.31%	-43.32%
MOLN Molecular Partners	-0.54%	-8.50%	-10.12%	-10.10%	+2.53%
NVCT Nuvectis Pharma	-0.83%	-11.29%	-22.91%	-3.23%	+198.51%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
CLYM Climb Bio	3.00	Buy	$27.62	153.12% Upside
DBVT DBV Technologies	2.67	Moderate Buy	$48.50	432.38% Upside
MOLN Molecular Partners	2.25	Hold	$8.38	123.63% Upside
NVCT Nuvectis Pharma	2.80	Moderate Buy	$36.25	91.49% Upside

Current Analyst Ratings Breakdown

Latest MOLN, NVCT, CLYM, and DBVT Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
10/12/2026	CLYM Climb Bio	HC Wainwright Subscribe to MarketBeat All Access to unlock brokerage rankings	Reiterated Rating	Buy
10/5/2026	CLYM Climb Bio	Raymond James Financial Subscribe to MarketBeat All Access to unlock brokerage rankings	Reiterated Rating	Strong-Buy	$34.00
10/2/2026	MOLN Molecular Partners	Weiss Ratings Subscribe to MarketBeat All Access to unlock brokerage rankings	Reiterated Rating	Sell (D-)
9/30/2026	DBVT DBV Technologies	Citigroup Subscribe to MarketBeat All Access to unlock brokerage rankings	Reiterated Rating	Market Outperform
9/24/2026	NVCT Nuvectis Pharma	HC Wainwright Subscribe to MarketBeat All Access to unlock brokerage rankings	Reiterated Rating	Buy	$39.00
9/21/2026	NVCT Nuvectis Pharma	Weiss Ratings Subscribe to MarketBeat All Access to unlock brokerage rankings	Upgrade	Sell (E+) ➝ Sell (D-)
9/16/2026	CLYM Climb Bio	Mizuho Subscribe to MarketBeat All Access to unlock brokerage rankings	Upgrade	Strong-Buy
9/10/2026	DBVT DBV Technologies	Cantor Fitzgerald Subscribe to MarketBeat All Access to unlock brokerage rankings	Reiterated Rating	Overweight
9/8/2026	CLYM Climb Bio	Oppenheimer Subscribe to MarketBeat All Access to unlock brokerage rankings	Boost Price Target	Outperform	$18.00 ➝ $25.00
9/8/2026	CLYM Climb Bio	HC Wainwright Subscribe to MarketBeat All Access to unlock brokerage rankings	Boost Price Target	Buy	$24.00 ➝ $30.00
9/7/2026	CLYM Climb Bio	Mizuho Subscribe to MarketBeat All Access to unlock brokerage rankings	Upgrade	Strong-Buy

(Data available from 10/15/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
CLYM Climb Bio	N/A	N/A	N/A	N/A	$3.36 per share	N/A
DBVT DBV Technologies	$5.64M	101.57	N/A	N/A	$4.20 per share	2.17
MOLN Molecular Partners	$5.65M	26.77	N/A	N/A	$2.40 per share	1.56
NVCT Nuvectis Pharma	N/A	N/A	N/A	N/A	$0.72 per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
CLYM Climb Bio	-$59.85M	-$0.83	N/A	N/A	N/A	N/A	-31.79%	-30.79%	11/11/2026 (Estimated)
DBVT DBV Technologies	-$146.95M	-$3.51	N/A	N/A	N/A	-3,506.53%	-119.33%	-84.43%	10/28/2026 (Estimated)
MOLN Molecular Partners	-$74.41M	-$1.71	N/A	N/A	N/A	N/A	-68.36%	-54.82%	10/29/2026 (Estimated)
NVCT Nuvectis Pharma	-$26.44M	-$1.31	N/A	N/A	N/A	N/A	-184.25%	-105.24%	11/3/2026 (Estimated)

Latest MOLN, NVCT, CLYM, and DBVT Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
11/11/2026	Q3 2026	CLYM Climb Bio	-$0.19	N/A	N/A	N/A	N/A	N/A
11/3/2026	Q3 2026	NVCT Nuvectis Pharma	-$0.22	N/A	N/A	N/A	N/A	N/A
10/29/2026	Q3 2026	MOLN Molecular Partners	-$0.46	N/A	N/A	N/A	N/A	N/A
10/28/2026	Q3 2026	DBVT DBV Technologies	-$0.1617	N/A	N/A	N/A	$0.66 million	N/A
8/25/2026	Q2 2026	MOLN Molecular Partners	-$0.45	-$0.44	+$0.01	-$0.43	N/A	N/A
8/6/2026	Q2 2026	CLYM Climb Bio	-$0.2093	-$0.18	+$0.0293	-$0.18	N/A	N/A
8/4/2026	Q2 2026	NVCT Nuvectis Pharma	-$0.2620	-$0.30	-$0.0380	-$0.30	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
CLYM Climb Bio	N/A	N/A	N/A	N/A	N/A
DBVT DBV Technologies	N/A	N/A	N/A	N/A	N/A
MOLN Molecular Partners	N/A	N/A	N/A	N/A	N/A
NVCT Nuvectis Pharma	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
CLYM Climb Bio	N/A	31.45	31.45
DBVT DBV Technologies	N/A	3.72	3.72
MOLN Molecular Partners	N/A	7.27	7.27
NVCT Nuvectis Pharma	N/A	1.68	1.68

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
CLYM Climb Bio	69.76%
DBVT DBV Technologies	71.74%
MOLN Molecular Partners	26.55%
NVCT Nuvectis Pharma	96.77%

Insider Ownership

Company	Insider Ownership
CLYM Climb Bio	2.60%
DBVT DBV Technologies	1.06%
MOLN Molecular Partners	5.93%
NVCT Nuvectis Pharma	28.55%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
CLYM Climb Bio	29	57.44 million	55.94 million	N/A
DBVT DBV Technologies	161	62.88 million	62.21 million	Optionable
MOLN Molecular Partners	134	40.38 million	37.98 million	Not Optionable
NVCT Nuvectis Pharma	13	32.64 million	23.32 million	Not Optionable

MOLN, NVCT, CLYM, and DBVT Headlines

Recent News About These Companies

Nuvectis Pharma (NASDAQ:NVCT) Stock Jumps 7.7% - What's Next?

October 15 at 1:39 PM | marketbeat.com

Nuvectis Pharma (NASDAQ:NVCT) Stock Price Down 6.8% - Should You Sell?

October 13 at 1:01 PM | marketbeat.com

Nuvectis Pharma (NASDAQ:NVCT) Shares Gap Up - What's Next?

October 12 at 11:19 AM | marketbeat.com

Nuvectis Pharma to Participate in the Maxim Growth Summit 2026

October 9, 2026 | globenewswire.com

Nuvectis Pharma (NASDAQ:NVCT) Stock Price Down 5.3% - Here's Why

October 5, 2026 | americanbankingnews.com

Nuvectis Pharma (NASDAQ:NVCT) Stock Price Down 5.3% - Time to Sell?

October 5, 2026 | marketbeat.com

Nuvectis Pharma, Inc. (NASDAQ:NVCT) Stock Has Consensus Target Price of $36.25 According to Brokerages

September 29, 2026 | marketbeat.com

Nuvectis' In-Licensed Cancer Drug Earned Breakthrough Designation in China, and It's Not Even Their Lead Asset

September 25, 2026 | markets.businessinsider.com

Nuvectis Pharma's NXP200 Granted Breakthrough Therapy Designation in China for High-Grade Glioma

September 24, 2026 | finance.yahoo.com

Nuvectis Pharma's (NVCT) Buy Rating Reaffirmed at HC Wainwright

September 24, 2026 | marketbeat.com

Nuvectis Announces NXP200 Granted Breakthrough Therapy Designation in China for BRAF V600-Mutant, Recurrent or Progressive, High-Grade Glioma

September 24, 2026 | globenewswire.com

Nuvectis Pharma (NASDAQ:NVCT) Shares Down 7.5% - Should You Sell?

September 23, 2026 | marketbeat.com

Nuvectis Pharma: Haisco Licensing Deal Revitalises Biotech - But No Rush To Invest Today

September 18, 2026 | seekingalpha.com

Nuvectis Pharma (NASDAQ:NVCT) Stock Price Down 5.6% - Should You Sell?

September 15, 2026 | marketbeat.com

Some of the Top Biotech Funds Just Bought Into This Under-the-Radar Biotech (NASDAQ: NVCT)

September 3, 2026 | markets.businessinsider.com

Nuvectis Pharma To Participate in Upcoming Investor Conferences

September 3, 2026 | globenewswire.com

Nuvectis Stock Surges Around 97% in 3 Months: Here's Why

August 19, 2026 | zacks.com

Analysts Offer Insights on Healthcare Companies: Nuvectis Pharma (NVCT) and EyePoint Pharmaceuticals (EYPT)

August 9, 2026 | theglobeandmail.com

Nuvectis’ NXP800 Ovarian Cancer Trial Terminated: What Investors Should Watch Next

August 6, 2026 | tipranks.com

Nuvectis Pharma Reports Second Quarter 2026 Financial Results and Business Highlights

August 4, 2026 | finance.yahoo.com

Nuvectis Pharma Reports Q2 2026 Results, Highlights In-Licensing of Ciprocopan and NXP200 and $115 Million Follow-On Offering

August 4, 2026 | quiverquant.comQ

New MarketBeat Followers Over Time

Media Sentiment Over Time

MOLN, NVCT, CLYM, and DBVT Company Descriptions

Climb Bio NASDAQ:CLYM

$10.91 +0.62 (+6.03%)

Closing price 04:00 PM Eastern

Extended Trading

$10.90 -0.02 (-0.14%)

As of 07:30 PM Eastern

Climb Bio Inc. is a clinical-stage biotechnology company developing therapeutics for patients with immune-mediated diseases. The Company's lead product candidate, budoprutug, is an anti-CD19 monoclonal antibody which has demonstrated B-cell depletion and has potential to treat a broad range of B-cell mediated diseases. Climb Bio Inc., formerly known as Eliem Therapeutics Inc., is based in WELLESLEY, Mass.

DBV Technologies NASDAQ:DBVT

$9.11 +0.24 (+2.71%)

Closing price 04:00 PM Eastern

Extended Trading

$9.10 -0.01 (-0.11%)

As of 04:04 PM Eastern

DBV Technologies S.A., a clinical-stage biopharmaceutical company, engages in the research and development of epicutaneous immunotherapy products. Its product pipeline comprising Viaskin Peanut, an immunotherapy product, which has completed Phase 3 clinical trial for the treatment of peanut allergies; and Viaskin Milk which is in Phase 1/2 clinical trial for the treatment of immunoglobulin E (IgE) mediated or cow's milk protein allergy and eosinophilic esophagitis. The company's earlier stage research programs includes vaccine for the respiratory syncytial virus, potential treatments for inflammatory bowel disease, celiac disease, and type I diabetes. In addition, it develops Viaskin technology platform, a platform to potentially treat food allergy. The company has a collaboration with Nestlé Health Science to develop MAG1C, a ready-to-use atopy patch test for the diagnosis of non-IgE mediated CMPA in infants and toddlers. DBV Technologies S.A. was incorporated in 2002 and is headquartered in Montrouge, France.

Molecular Partners NASDAQ:MOLN

$3.74 +0.10 (+2.60%)

As of 04:00 PM Eastern

Molecular Partners AG, a clinical-stage biotechnology company, develops designed ankyrin repeat proteins therapeutics for the treatment of oncology and virology diseases in Switzerland. The company develops MP0317, a CD40 agonist designed to activate immune cells within the tumor microenvironment by anchoring to fibroblast activation protein that is in Phase I clinical trial; and MP0533, a novel tetra-specific T cell-engaging DARPin for acute myeloid leukemia. It also develops Switch-DARPin platform, a multispecific cKIT x CD16a x CD47 Switch-DARPin program for targeted and conditional immune cell activation; and Radio-DARPin Therapy (RDT) platform, a delivery system for effective and selective delivery of radioactive payloads to solid tumors. It has license and research collaboration agreements with Novartis Pharma AG to develop DARPin-conjugated radioligand therapies; and collaboration agreement with Orano Med SAS to develop novel Radio-DARPin therapeutics. Molecular Partners AG was incorporated in 2004 and is headquartered in Schlieren, Switzerland.

Nuvectis Pharma NASDAQ:NVCT

$18.93 +0.93 (+5.17%)

Closing price 04:00 PM Eastern

Extended Trading

$18.89 -0.04 (-0.21%)

As of 07:30 PM Eastern

Nuvectis Pharma, Inc., a biopharmaceutical company, focuses on the development of precision medicines for the treatment of serious unmet medical needs in oncology. The company's lead product candidate is NXP800, a novel small molecule that is in Phase 1b clinical trials for the treatment of patients with platinum-resistant, ARID1a-mutated ovarian carcinoma. It is also developing NXP900, a small molecule drug candidate, which is in Phase 1a clinical trails that inhibits the Proto-oncogene c-Src and YES1 kinases. It has license agreement with the CRT Pioneer Fund for the NXP800 and any of related derivatives; and the University of Edinburgh for the NXP900 and any of associated derivatives. The company was formerly known as Centry Pharma, Inc. and changed its name to Nuvectis Pharma, Inc. in July 2021. Nuvectis Pharma, Inc. was incorporated in 2020 and is based in Fort Lee, New Jersey.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest MOLN, NVCT, CLYM, and DBVT Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest MOLN, NVCT, CLYM, and DBVT Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

MOLN, NVCT, CLYM, and DBVT Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

MOLN, NVCT, CLYM, and DBVT Company Descriptions

Climb Bio NASDAQ:CLYM

DBV Technologies NASDAQ:DBVT

Molecular Partners NASDAQ:MOLN

Nuvectis Pharma NASDAQ:NVCT

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest MOLN, NVCT, CLYM, and DBVT Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest MOLN, NVCT, CLYM, and DBVT Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

MOLN, NVCT, CLYM, and DBVT Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

MOLN, NVCT, CLYM, and DBVT Company Descriptions

Climb Bio NASDAQ:CLYM

DBV Technologies NASDAQ:DBVT

Molecular Partners NASDAQ:MOLN

Nuvectis Pharma NASDAQ:NVCT

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools